About

Black and white image of Tobias Ripsom, CEO of GALYNA

TOBIAS RIPSOM

CHIEF EXECUTIVE OFFICER | CO-FOUNDER

Toby directs GALYNA’s plant-powered solutions into the skin care universe. As the co-founder of Veritas Fine Cannabis, Colorado’s original craft cannabis, Toby had a front row seat to the first adult-use legalization of cannabis and hemp. In that era, the power of superiorly cultivated trees, and their magical budding flowers was all encompassing. Seeing this, he began to cobble together concepts friendlier to the masses yet still rooted in his gardens. It was clear, the game changing plant matter he processed everyday could also be a packaged good. After suffering from a lifetime of troubled skin and now aging out of its resiliency, he partnered with topical industry veterans to dabble with benchtop prototypes. Toby’s fascination with real results from illicit ingredients grew irresistible. Never satisfied with the proof behind claims, nor touch and feel of dispensary offerings versus what he saw in department store skin care, he set out to prove cannabinoids benefited every body.

Toby brought almost a decade of operational, financial and marketing management prowess from real estate related endeavors to the cultivation arena of Denver circa 2014. His company helped pioneer America’s first legal marketplace and legitimize the alternative vice through professional trust and best in class craftsmanship. Nearly a decade later, he is still learning daily how plant power can improve lives and bodies, then turning that knowledge into the next skin solution.

A one-time Nordic ski racer for both the Sun Valley Ski Education Foundation and University of New Hampshire Wildcats, he can still be found testing GALYNA formulations, both before, during and after endless high-altitude kilometers.  A husband and father of two sons, he and his family reside in Denver, Colorado.

 

Black and white image of GALYNA's Chief Scientific Officer, Marnie Peterson

MARNIE PETERSON, PHARMD, PHD

CHIEF SCIENTIFIC OFFICER 

Dr. Marnie Peterson is an entrepreneur, innovator, and expert in infectious diseases. She has 25+ years of experience in the development and discovery of new therapeutics related to infectious diseases and wound healing. In 2016, she founded and became the CEO of Jackson, Wyoming-based Extherid Biosciences to focus on new approaches to preclinical research including live animal alternatives (ex vivo tissue models) that aim to accelerate and predict clinical outcomes. This unique approach to technology development led to research collaborations with the FDA, academics, and global companies in the pharmaceutical, medical device and cosmetic industries.

In 2020, Extherid merged with UK-based Perfectus Biomed and became Perfectus Biomed, LLC, which operated as a US-based subsidiary of Perfectus Biomed Group. The new entity brought together over 60 employees focused on improving lives through innovative science. Marnie was the US Managing Director and CSO of Perfectus Biomed Group which was uniquely positioned to support global clients from preclinical development and throughout the regulatory stage. In 2022, Perfectus Biomed Group was acquired by NAMSA to expand the expertise and service offerings in customized microbiology to the MedTech industry globally. Marnie continues serves as a consultant to the Center for Infectious Disease Research and Policy at the University of Minnesota and hosts a podcast Superbugs and You. Before establishing Extherid, Marnie was tenured faculty at the University of Minnesota in the Department of Experimental and Clinical Pharmacology for 11 years. At the University, she established a research program and led multimillion-dollar research projects with the National Institutes of Health, Department of Defense, and various foundations and industrial partners. In 2014, the Minnesota Business Magazine selected Marnie as a Change Agent finalist for the Leaders in Health Care Awards. She earned a PhD in Infection from the University of Birmingham Medical School, United Kingdom and PharmD and BS degrees from the University of Minnesota.

She has published over 50 scientific manuscripts in peer-reviewed journals including Nature and holds a significant patent portfolio for her discoveries, which serve as the basis for a clinical stage women’s health company, Hennepin Life Sciences that was licensed to Dare Biosience. Importantly, these patents, experiences and life lessons informed her role as CSO of GALYNA.

In 2014, the Minnesota Business Magazine selected Marnie as a Change Agent finalist for the Leaders in Health Care Awards. She earned a PhD in Infection from the University of Birmingham Medical School, United Kingdom and PharmD and BS degrees from the University of Minnesota.

Contact Us